Top

Published in:

Open Access 01-12-2010 | Research

Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes

Authors: Anna Mordalska, Joanna Latek, Tomasz Ferenc, Lech Pomorski, Elżbieta Gałecka, Arkadiusz Zygmunt, Andrzej Lewiński

Published in: Thyroid Research | Issue 1/2010

Abstract

Background

At present, researchers' attention has been concentrating on NDRG2 (N-Myc downstream-regulated gene 2) as a new gene candidate in the development and progression of papillary thyroid carcinoma (PTC). NDRG2, together with NDRG1, NDRG3 and NDRG4 are members of the NDRG family, a new class of genes, inhibited by N-Myc oncogene.

Aim

The aim of our study was to evaluate NDRG2 mRNA expression in the primary PTC and its metastases to regional lymph nodes.

Materials and methods

Postoperative tissue and macroscopically changed lymph nodes of sixteen (16) patients with PTC constituted the studied material. In this group, metastases of the cancer to regional lymph nodes were confirmed histopathologically in 8 cases. Quantitative evaluation of NDRG2 mRNA expression was performed by the real-time polymerase chain reaction (real-time PCR) method.

Results

The mean values of NDRG2 mRNA expression in the primary tumour tissues were statistically significantly lower vs. the levels of NDRG2 mRNA expression in macroscopically unchanged thyroid tissue (p < 0.0001). A comparison of the mean NDRG2 mRNA expression of primary tumours and that of their metastases to regional lymph nodes did not demonstrate any statistical differences (p > 0.05). A positive correlation was observed between NDRG2 mRNA expression in primary tumour cells and in the cancer metastases to lymph nodes (Rs = 0.7857; p < 0.05). Factors, such as age, sex, tumour stage in TNM system, were of no significance for NDRG2 mRNA expression level (p > 0.1).

Conclusion

The results of our study demonstrated decreased NDRG2 mRNA expression levels in PTC, when compared to macroscopically unchanged thyroid tissue, which may point to the potential role of NDRG2 in the development and progression of cancer in question.

Available only for authorised users

Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30: 216–222. 10.1097/01.pas.0000176432.73455.1bPubMedCrossRef

Nikiforov Y: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, (Suppl 2):S37-S43. 10.1038/modpathol.2008.10

Sherman SI: Thyroid carcinoma. Lancet 2003, 361: 501–511. 10.1016/S0140-6736(03)12488-9PubMedCrossRef

Lewiński A, Ferenc T, Sporny S, Jarząb B: Thyroid carcinoma: diagnostic nad therpeutic approach; genetic background (review). Endocrine Regul 2000, 34: 99–113.

Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, Han H, Nie X, Li Q, Kung HF, Leung SY, Lin MC: N-Myc downstream-regulated gene 2 ( NDRG2 ) inhibits glioblastoma cell proliferation. Int J Cancer 2003, 106: 342–347. 10.1002/ijc.11228PubMedCrossRef

Yao L, Zhang J, Liu X: NDRG2 : aa Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin 2008, 40: 625–635. 10.1111/j.1745-7270.2008.00434.xPubMedCrossRef

Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F: Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem 2002, 229: 35–44. 10.1023/A:1017934810825PubMedCrossRef

Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, Wu Y, Shen L, Zhang Y, Han H, Zhang J, Yao L: Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun 2007, 358: 164–169. 10.1016/j.bbrc.2007.04.089PubMedCrossRef

Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A: Integrative genomic analysis identifies NDRG2 gene as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 2005, 65: 7121–7126. 10.1158/0008-5472.CAN-05-0043PubMedCrossRef

10.

Lorentzen A, Vogel LK, Lewinsky RH, Sæbø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 2007, 7: 192–198. 10.1186/1471-2407-7-192PubMedCentralPubMedCrossRef

11.

Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Wu Y, Ji S, Zhang Y, Yang A, Han H, Yao L: N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res 2008, 36: 5335–5349. 10.1093/nar/gkn504PubMedCentralPubMedCrossRef

12.

Hoffman B, Liebermann DA: Apoptotic signaling by c-MYC. Oncogene 2008, 27: 6462–6472. 10.1038/onc.2008.312PubMedCrossRef

13.

Zhao H, Zhang J, Lu J, He X, Chen C, Li X, Gong L, Bao G, Fu Q, Lin W, Shi H, Ma J, Liu X, Ma Q, Yao L: Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 2008, 8: 303–311. 10.1186/1471-2407-8-303PubMedCentralPubMedCrossRef

14.

DeLellis RA, Lloyd RV, Heitz PU, Eng C: World Health Organization. Classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon; 2004.

15.

Hunt JL, LiVolsi VA, Baloch ZW, Barnes EL, Swalsky PA, Niehouse L, Finkelstein SD: Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss heterozygosity mutational profile. Am J Surg Pathol 2003, 27: 159–166. 10.1097/00000478-200302000-00003PubMedCrossRef

16.

Lin JD, Chen ST, Chao TC, Hsueh C, Weng HF: Diagnosis and therapeutic strategy for papillary thyroid microcarcinoma. Arch Surg 2005, 140: 940–945. 10.1001/archsurg.140.10.940PubMedCrossRef

17.

Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A: Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr J 2010, 57: 523–531. 10.1507/endocrj.K10E-019PubMedCrossRef

18.

Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH, Yang Y, Lim JS, Lee HG: Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med 2007, 39: 705–714.PubMedCrossRef

19.

Stark AM, Tongers K, Mehdorn HM, Held-Feindt J: Reduced metastasis-supressor gene mRNA-expression in breast cancer metastases. J Cancer Res Clin Oncol 2005, 131: 191–198. 10.1007/s00432-004-0629-9PubMedCrossRef

20.

Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X, Yao LB: NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol 2004, 10: 3518–3521.PubMed

21.

Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang X, Zhang W, Zhao H, Yao L: Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 2008, 31: 1316–1320. 10.1248/bpb.31.1316PubMedCrossRef

22.

Hummerich L, Müller R, Hess J, Kokocinski F, Hahn M, Fürstenberger G, Mauch C, Lichter P, Angel P: Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 2006, 25: 111–121.PubMed

23.

Stark AM, Tongers K, Mehdorn HM, Held-Feindt J: Reduced metastasis-supressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 2005, 131: 191–198. 10.1007/s00432-004-0629-9PubMedCrossRef

Title: Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes
Authors: Anna Mordalska
Joanna Latek
Tomasz Ferenc
Lech Pomorski
Elżbieta Gałecka
Arkadiusz Zygmunt
Andrzej Lewiński
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Thyroid Research / Issue 1/2010
Electronic ISSN: 1756-6614
DOI: https://doi.org/10.1186/1756-6614-3-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes

Abstract

Background

Aim

Materials and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Aim

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Effect of thyroid statuses on sodium/iodide symporter (NIS) gene expression in the extrathyroidal tissues in mice

Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report

Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer

Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR

Acute myocardial infarction as the first presentation of thyrotoxicosis in a 31-year old woman - case report

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page